SEOUL, KOREA - Hanmi Pharm surpassed the 100-billion-won level in R&D spending last year, first among Korea’s publicly listed pharmaceutical companies. The drug company is now engaged in a total of 29 R&D projects, including seven biosimilar projects and seven new compound medicine projects.
Even in 2010 when it suffered its first-ever deficit, Hanmi Pharm injected 85.2 billion won into R&D. It spent 74 billion won for R&D in 2011 and 79.5 billion won in 2012. The company has allocated 14 percent of its annual sales for R&D. In 2013, it is estimated to have spent 100 billion won for R&D.
The company expects its R&D spending to increase further in 2014 as its global clinical project for new diabetes medicines will be actively pursued.
저작권자 © Korea IT Times 무단전재 및 재배포 금지
